Insufficient sleep has been associated with difficulty focusing, impaired memory, impaired decision-making, and slower reaction times. This underscores the importance of treating and managing insomnia for employability, safety, and quality of life. According to the DSM-5, the diagnosis of insomnia is based not only on nighttime sleep issues but also daytime impairment that can impact a patient’s academic, social or work life. In a recent study, 73% of insomnia patients complained of challenges falling asleep, and 84% experienced issues with daily functioning.
In clinical trials, patients taking daridorexant (Quviviq) 50 mg reported improvements in daytime sleepiness versus placebo as measured by the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ). This improvement started 1 week after the initial administration and continued to improve over time. Statistically significant nighttime improvements versus placebo were also seen in falling asleep faster, staying asleep longer, and increased total time asleep. These results could be promising since many sleep medications are associated with next-day hangover effects.
Why do you think that patients taking daridorexant 50 mg showed a statistically significant reduction in daytime sleepiness vs placebo? What factors may be contributing to this finding?